Clinical Trials Browser

Graft vs Host Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05949762 2023-07-18

Safety and Efficacy of Venetoclax in Combination With Azacitidine and HA Regimen in the Treatment of AML in the Elderly

Phase 1/2 Unknown

45 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05503355 2023-04-04

A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML

Phase 1/2 Unknown

80 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05312112 2023-03-02

Real World Outcomes Using Novel Agents for AML in the UK

Unknown

1,000 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05654194 2022-12-16

Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML

Phase 3 Unknown

30 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05522192 2022-08-30

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia

Phase 1/2 Unknown

70 enrolled

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT05362942 2022-05-05

Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia

Phase 2 Unknown

52 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT05053425 2022-04-26

Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML

Phase NA Unknown

30 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05262465 2022-03-02

Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML

Phase NA Unknown

300 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04613622 2021-10-28

Pharmacokinetics of Venetoclax in Patients With Acute Myeloid Leukemia

Unknown

500 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04824924 2021-04-01

A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive Chemotherapy

Phase 2 Unknown

100 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03662724 2021-02-16

VENreg

Unknown

100 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04454580 2020-09-16

Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy

Unknown

15 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01211457 2019-07-16

Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

Phase 1/2 Unknown

65 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

Clinical Trials

V-FIRST

RELAX

Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies

Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia

Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML

Viale-a

Venetoclax and Lintuzumab-Ac225 in AML Patients

VICTORY

Safety and Efficacy of Venetoclax in Combination With Azacitidine and HA Regimen in the Treatment of AML in the Elderly

A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML

Real World Outcomes Using Novel Agents for AML in the UK

Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia

Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia

Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML

Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML

Pharmacokinetics of Venetoclax in Patients With Acute Myeloid Leukemia

A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive Chemotherapy

VENreg

Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy

Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)